Venetoclax-Based Regimens in Newly Diagnosed FLT3-Mutated Older or Unfit Acute Myeloid Leukemia: A Systematic Review and Meta-Analysis of Comparative and Single-Arm Outcomes.
Older or medically unfit patients with newly diagnosed FLT3-mutated acute myeloid leukemia (AML) have poor outcomes with hypomethylating agent (HMA) monotherapy. On current evidence, triplets are a promising biologically rational strategy requiring direct randomized validation against the contemporary VEN-HMA standard.
Older or medically unfit patients with newly diagnosed FLT3-mutated acute myeloid leukemia (AML) have poor outcomes with hypomethylating agent (HMA) monotherapy. On current evidence, triplets are a promising biologically rational strategy requiring direct randomized validation against the contemporary VEN-HMA standard.
What the study was
- Study design
- Meta-analysis
- Population
- Older or medically unfit patients with newly diagnosed FLT3-mutated acute myeloid leukemia (AML) have poor outcomes with hypomethylating agent (HMA) monotherapy.
- Category
- Treatment Innovation
- Maturity
- Validated
- Journal
- Hematological oncology
Why it surfaced
Meta-analysis with abstract evidence; scored conservatively for novelty, clinical relevance, design quality, and population or unmet need.
A plain-language summary of published research — not medical advice. Talk to a clinician about your own care.